Michelle Lewis has spent much of her over 20 year career as a member of in-house legal departments such as Genetech and Bristol Myers Squibb, and supported the successful “exits” of ZymoGenetics (bought by BMS), Molecular Templates, and Capsugel (bought by Lonza).  A true client’s advocate, she works to forward the business goals of her clients. Michelle’s expertise covers large and small molecule therapeutics, gene therapies, stem cell therapies, diagnostic testing, next generation sequencing methods, and medical devices.  Michelle has also worked as a patent agent and patent examiner at the USPTO.